PL3808774T3 - Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne - Google Patents
Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczneInfo
- Publication number
- PL3808774T3 PL3808774T3 PL19852040.5T PL19852040T PL3808774T3 PL 3808774 T3 PL3808774 T3 PL 3808774T3 PL 19852040 T PL19852040 T PL 19852040T PL 3808774 T3 PL3808774 T3 PL 3808774T3
- Authority
- PL
- Poland
- Prior art keywords
- human
- medical use
- antigen binding
- binding fragment
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810971269 | 2018-08-24 | ||
| CN201811472752 | 2018-12-04 | ||
| CN201910221311 | 2019-03-22 | ||
| CN201910401923 | 2019-05-15 | ||
| PCT/CN2019/102169 WO2020038454A1 (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3808774T3 true PL3808774T3 (pl) | 2025-06-23 |
Family
ID=69591987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19852040.5T PL3808774T3 (pl) | 2018-08-24 | 2019-08-23 | Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12162944B2 (pl) |
| EP (1) | EP3808774B1 (pl) |
| JP (1) | JP7405831B2 (pl) |
| KR (1) | KR102840973B1 (pl) |
| CN (2) | CN112513090B (pl) |
| AU (1) | AU2019324403A1 (pl) |
| BR (1) | BR112021002989A2 (pl) |
| CA (1) | CA3105527A1 (pl) |
| ES (1) | ES3028305T3 (pl) |
| MX (1) | MX2021001143A (pl) |
| MY (1) | MY205774A (pl) |
| PL (1) | PL3808774T3 (pl) |
| TW (1) | TWI840399B (pl) |
| WO (1) | WO2020038454A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113527485B (zh) * | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| CN111996172A (zh) * | 2020-09-08 | 2020-11-27 | 中国食品药品检定研究院 | 一种用于测定il-4靶向治疗性抗体生物学活性的方法 |
| WO2022135441A1 (zh) | 2020-12-22 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体或其抗原结合片段的复合物及医药用途 |
| CN114652853B (zh) * | 2020-12-22 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体-药物偶联物及医药用途 |
| MX2024009080A (es) | 2022-01-29 | 2024-07-30 | Shanghai Shengdi Pharmaceutical Co Ltd | Conjugado farmacologico de glucocorticoide. |
| IL316264A (en) | 2022-05-02 | 2024-12-01 | Regeneron Pharma | Antibody formulations against interleukin-4 receptor (IL-4R) |
| AU2023265659A1 (en) | 2022-05-02 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
| US20260109758A1 (en) * | 2022-09-22 | 2026-04-23 | Biosion, Inc. | Recombinant bispecific antibodies targeting tslp and il4r |
| AU2024241290A1 (en) * | 2023-03-22 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist |
| CN121568722A (zh) | 2023-07-28 | 2026-02-24 | 江苏恒瑞医药股份有限公司 | 一种含有糖皮质激素的抗体药物偶联物的药物组合物 |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025108394A1 (zh) * | 2023-11-22 | 2025-05-30 | 联邦生物科技(珠海横琴)有限公司 | 抗IL-4Rα抗体或其抗原结合片段及其双特异性抗体和应用 |
| CN117924490B (zh) * | 2023-12-22 | 2024-10-22 | 华润生物医药有限公司 | 抗il-4r抗体及其用途 |
| CN117924491B (zh) * | 2023-12-22 | 2024-10-18 | 华润生物医药有限公司 | 抗il-4r抗体及其用途 |
| WO2026055687A1 (en) | 2024-09-09 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Methods for treating bullous pemphigoid by administering an il-4r antagonist |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| KR101759457B1 (ko) * | 2007-12-21 | 2017-07-31 | 메디뮨 리미티드 | 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173 |
| EP3539985A1 (en) * | 2012-02-24 | 2019-09-18 | AbbVie Stemcentrx LLC | Anti sez6 antibodies and methods of use |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| CA2959571A1 (en) | 2014-09-03 | 2016-03-10 | Medimmune Limited | Stable anti-il-4r-alpha antibody formulation |
| CA2980087A1 (en) * | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| CN108339118A (zh) * | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
| CN108409860B (zh) | 2017-02-10 | 2021-10-15 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 |
| CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
-
2019
- 2019-08-23 US US17/269,449 patent/US12162944B2/en active Active
- 2019-08-23 CA CA3105527A patent/CA3105527A1/en active Pending
- 2019-08-23 MY MYPI2020007165A patent/MY205774A/en unknown
- 2019-08-23 JP JP2021508304A patent/JP7405831B2/ja active Active
- 2019-08-23 BR BR112021002989-3A patent/BR112021002989A2/pt unknown
- 2019-08-23 KR KR1020217004544A patent/KR102840973B1/ko active Active
- 2019-08-23 ES ES19852040T patent/ES3028305T3/es active Active
- 2019-08-23 PL PL19852040.5T patent/PL3808774T3/pl unknown
- 2019-08-23 TW TW108130264A patent/TWI840399B/zh active
- 2019-08-23 CN CN201980050263.4A patent/CN112513090B/zh active Active
- 2019-08-23 AU AU2019324403A patent/AU2019324403A1/en active Pending
- 2019-08-23 EP EP19852040.5A patent/EP3808774B1/en active Active
- 2019-08-23 MX MX2021001143A patent/MX2021001143A/es unknown
- 2019-08-23 CN CN202310069400.7A patent/CN115991781A/zh active Pending
- 2019-08-23 WO PCT/CN2019/102169 patent/WO2020038454A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN112513090A (zh) | 2021-03-16 |
| ES3028305T3 (en) | 2025-06-18 |
| JP2021533792A (ja) | 2021-12-09 |
| MX2021001143A (es) | 2021-04-12 |
| BR112021002989A2 (pt) | 2021-05-11 |
| CA3105527A1 (en) | 2020-02-27 |
| AU2019324403A1 (en) | 2021-01-28 |
| US20210238294A1 (en) | 2021-08-05 |
| MY205774A (en) | 2024-11-12 |
| KR20210049792A (ko) | 2021-05-06 |
| TWI840399B (zh) | 2024-05-01 |
| US12162944B2 (en) | 2024-12-10 |
| JP7405831B2 (ja) | 2023-12-26 |
| TW202023612A (zh) | 2020-07-01 |
| CN115991781A (zh) | 2023-04-21 |
| EP3808774B1 (en) | 2025-04-16 |
| KR102840973B1 (ko) | 2025-07-30 |
| EP3808774A4 (en) | 2021-08-18 |
| EP3808774C0 (en) | 2025-04-16 |
| CN112513090B (zh) | 2023-03-10 |
| WO2020038454A1 (zh) | 2020-02-27 |
| EP3808774A1 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3808774T3 (pl) | Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne | |
| EP3689909A4 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
| EP3632932A4 (en) | ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE | |
| IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
| ZA202104518B (en) | Cd3 antibody and pharmaceutical use thereof | |
| ZA202006904B (en) | Anti-il-4r antibody and use thereof | |
| ZA201700528B (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| EP3892634A4 (en) | ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF | |
| IL275243A (en) | Bispecific antigen-binding molecules that bind leptin and/or GP130 receptor and methods of using them | |
| DK3638698T3 (da) | Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter | |
| SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
| ZA202004907B (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| IL290551A (en) | Antibodies against ilt2 and their use | |
| EP3778636A4 (en) | ANTI-CD27 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED MEDICAL USE | |
| EP3378871A4 (en) | PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF | |
| WO2017123636A8 (en) | Dosage and administration of anti-c5 antibodies for treatment | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| EP3587452A4 (en) | ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT | |
| EP3733703A4 (en) | Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment | |
| SG11202011201QA (en) | Fully human antibodies against ox40, method for preparing same, and use thereof | |
| IL291082A (en) | Anti-vsig4 antibody or antigen-binding fragment and uses thereof | |
| EP4006055A4 (en) | ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | |
| ZA202001807B (en) | Il-5 antibody, antigen binding fragment thereof, and medical application therefor | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL291049A (en) | Anti-cd47 monoclonal antibody and use thereof |